[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Controversies
July 2007

Topical Antibiotic Prophylaxis in Intraocular Injections

Author Affiliations

Author Affiliation: Department of Ophthalmology, School of Medicine, Stanford University, Stanford, California.

 

LEE M.JAMPOLMD

Arch Ophthalmol. 2007;125(7):972-974. doi:10.1001/archopht.125.7.972

Intraocular injections of therapeutic agents are becoming standard therapy for many diseases involving the retina. For example, intravitreous injections of triamcinolone acetonide are now commonly used for the treatment of macular edema due to diabetic retinopathy.1,2 In addition, the recent approval of Macugen (Pfizer Inc, New York, New York) and Lucentis (Genentech, South San Francisco, California) by the Food and Drug Administration is expected to result in a dramatic increase in the number of intraocular injections for the treatment of macular degeneration.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×